---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-087678"
form_type: "8-K"
ticker: "GUTS"
cik: "0001572616"
company_name: "FRACTYL HEALTH, INC."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T02:57:19.957183+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Fractyl Health gets two new U.S. patents for duodenal resurfacing, portfolio now 31 granted patents

## Summary
- U.S. Patent No. 12,329,439 (June 17, 2025) and No. 12,303,185 (May 20, 2025) cover thermal and non-thermal electrical energy ablation of duodenal mucosa.
- Total IP estate: 31 granted U.S. patents and ~40 pending applications, built since 2011.
- Revita next milestones: REVEAL-1 open-label data June 2025, REMAIN-1 midpoint Q3 2025, primary endpoint H2 2026.
- Patents reinforce Fractyl's leadership in gut-targeted metabolic therapies for obesity and type 2 diabetes.

## SEC filing metadata
- accession: 0000950170-25-087678
- form_type: 8-K
- ticker: GUTS
- cik: 0001572616
- company_name: FRACTYL HEALTH, INC.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1572616/000095017025087678/0000950170-25-087678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1572616/000095017025087678/guts-20250618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-087678
- JSON: https://secwatch.observer/filing/0000950170-25-087678.json
- Plain text: https://secwatch.observer/filing/0000950170-25-087678.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.